LTRN Stock Overview A clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Lantern Pharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lantern Pharma Historical stock prices Current Share Price US$3.13 52 Week High US$11.99 52 Week Low US$2.79 Beta 1.55 1 Month Change 1.46% 3 Month Change -20.28% 1 Year Change -23.41% 3 Year Change -58.72% 5 Year Change n/a Change since IPO -79.10%
Recent News & Updates
Lantern Pharma Inc. Announces First Patient Enrolled in Taiwan for Phase 2 Harmonic Clinical Trial of LP-300 in never-Smoker NSCLC Patients Dec 10
Lantern Pharma Inc.'S Investigational Drug-Candidate, Lp-184, Receives Second Fast Track Designation from Fda for Treatment of Triple Negative Breast Cancer Dec 04
Lantern Pharma Inc. Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic Clinical Trial of LP-300 in Never-Smoker NSCLC Patients Nov 20
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? Nov 05
Lantern Pharma Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Lantern Pharma's Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation in Glioblastoma from the Fda Oct 16 See more updates
Lantern Pharma Inc. Announces First Patient Enrolled in Taiwan for Phase 2 Harmonic Clinical Trial of LP-300 in never-Smoker NSCLC Patients Dec 10
Lantern Pharma Inc.'S Investigational Drug-Candidate, Lp-184, Receives Second Fast Track Designation from Fda for Treatment of Triple Negative Breast Cancer Dec 04
Lantern Pharma Inc. Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic Clinical Trial of LP-300 in Never-Smoker NSCLC Patients Nov 20
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth? Nov 05
Lantern Pharma Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Lantern Pharma's Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation in Glioblastoma from the Fda Oct 16
Lantern Pharma Highlights Promising Preclinical Results of LP-184'S Synergy with Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson At Immuno-Oncology Summit 2024 Aug 08
Lantern Pharma Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for Use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 Jul 11
Lantern Pharma Inc.(NasdaqCM:LTRN) dropped from Russell 3000E Value Index Jul 03
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans Jun 12
Lantern Pharma Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Lantern Pharma Inc., Annual General Meeting, Jun 13, 2024 May 01
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan Apr 23
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284 Mar 15
Lantern Pharma Inc. to Report Q4, 2023 Results on Mar 18, 2024 Mar 12
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR Mar 06
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Feb 28
Lantern Pharma Advances Unique ADC Program Across Multiple Solid Tumor Cancers Feb 15
New minor risk - Share price stability Nov 10
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate Nov 06
Lantern Pharma Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Lantern Pharma Inc. Announces the Death of Dr. Franklyn Prendergast, a Director of the Company Oct 22
Lantern Pharma Inc. Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of Lp-184 in Glioblastoma Oct 05
Lantern Pharma Inc. Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors Sep 26
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas Sep 19
Lantern Pharma Inc. to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting Sep 01
Lantern Pharma Inc. Expands AI Capabilities of RADR(R) Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors Aug 29
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans Jul 20
Oncotarget Publishes New Data by Lantern Pharma Further Supporting Clinical Advancement of LP-284, A Novel Synthetic Lethal Drug Candidate for Non-Hodgkin's Lymphomas Jun 27
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors Jun 13
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University Jun 09
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Apr 04
Lantern Pharma Inc. Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates Feb 16
Lantern Pharma Inc. Receives Pre-IND Feedback from the FDA Jan 18
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation Dec 19
Lantern Pharma Inc. Announces Positive New Data for Its Drug Candidate LP-284 for Mantle Cell Lymphoma Dec 17
Lantern Pharma Inc. Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) Dec 14
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate Lp-184 for Glioblastoma Nov 23
Price target decreased to US$18.50 Nov 16
Lantern Pharma Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 01
Lantern Pharma Inc. to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting Sep 24
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Sep 02
Lantern Pharma Receives Food and Drug Administration Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer Jul 15
Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer Jul 14
Price target decreased to US$26.00 May 24
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth May 20
Lantern Pharma Inc. Announces Leslie W. Kreis, Jr. Not to Stand for Reelection as A Director Apr 27
Lantern Pharma Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 23
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation Feb 02
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for Lp-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor Jan 25
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology Dec 15
Lantern Pharma Inc. (NasdaqCM:LTRN) announces an Equity Buyback for $7 million worth of its shares. Nov 24
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely Oct 13
Price target increased to US$29.50 Sep 19
Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer Aug 24
Lantern Pharma: Drug Recycling With AI Jun 08
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate May 05
Lantern Pharma reports Q1 results May 03
Lantern Pharma Announces That RADR® Has Exceeded 4.6 Billion Datapoints Apr 30
Lantern Pharma Inc. Announces Publication Detailing Preclinical Results of Drug Candidate, LP-184, in a Spectrum of Drug-Resistant Lung Cancers in the Journal Oncotarget Apr 27
Lantern Pharma Inc. Announces Filing of Seven Patent Applications Globally on Novel DNA-Damaging Agent with Anticancer Properties Mar 18
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like Feb 19
Lantern Pharma Inc. has completed a Follow-on Equity Offering in the amount of $60.00001 million. Jan 15
New 90-day low: US$14.51 Jan 15 Lantern Pharma Inc. and AF Chemicals, LLC Enter into Second Addendum to Technology License Agreement
Lantern Pharma Announces Launch of Antibody Drug Conjugate (Adc) Program to Target Solid Tumors & Blood Cancers Through Agreement with Califia Pharma Jan 06
Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma Jan 04
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares? Dec 28
Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma Dec 19
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers Dec 17
Lantern: Early Stage 'Smart Drug' Discovery Company Nov 25
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, A Next-Generation, Targeted DNA-Damaging Agent Oct 06
New 90-day high: US$21.25 Sep 29
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer Sep 23
New 90-day high - US$19.24 Sep 12 Shareholder Returns LTRN US Biotechs US Market 7D -8.9% -3.3% -2.2% 1Y -23.4% -1.9% 23.9%
See full shareholder returns
Return vs Industry: LTRN underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: LTRN underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is LTRN's price volatile compared to industry and market? LTRN volatility LTRN Average Weekly Movement 11.4% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: LTRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LTRN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation.
Show more Lantern Pharma Inc. Fundamentals Summary How do Lantern Pharma's earnings and revenue compare to its market cap? LTRN fundamental statistics Market cap US$33.70m Earnings (TTM ) -US$19.09m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LTRN income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$19.09m Earnings -US$19.09m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 01:27 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lantern Pharma Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kyle Bauser Colliers Securities Ashok Kumar ThinkEquity LLC John Vandermosten Zacks Small-Cap Research
Show 0 more analysts 
